Details for Patent: 8,114,890
✉ Email this page to a colleague
Title: | Anti-constipation composition |
Abstract: | An object of the present invention is to provide an anti-constipation composition containing a halogenated-bi-cyclic compound as an active ingredient in ratio of bi-cyclic/mono-cyclic structure of at least 1:1. The halogenated-bi-cyclic compound is represented by Formula (I): ##STR00001## where X.sub.1 and X.sub.2 are preferably both fluorine atoms. The composition can be used to treat constipation with out substantive side-effects, such as stomachache. |
Inventor(s): | Ueno; Ryuji (Potomac, MD) |
Assignee: | Sucampo AG (Zurich, CH) |
Filing Date: | Oct 17, 2011 |
Application Number: | 13/274,612 |
Claims: | 1. A liquid dosage form for oral administration comprising: a bi-cyclic compound represented by the formula (I), ##STR00028## 13,14-dihydro-15-keto-16,16-difluoro-prostaglandin E1 a compound which is a mono-cyclic tautomer of formula (I), and a non-aqueous solution or suspension agent, wherein the non-aqueous solvent or suspending agent stabilizes the dosage form in a ratio of bi-cyclic compound to mono-cyclic tautomer of at least 20:1. 2. The liquid dosage form of claim 1, wherein the non-aqueous solution or suspension agent is propylene glycol, polyethylene glycol, alcohol, or polysorbate. 3. The liquid dosage form of claim 1, wherein the non-aqueous solution or suspension agent is propylene glycol, polyethylene glycol, a fatty acid triglyceride, a vegetable oil, or an alcohol. 4. The liquid dosage form of claim 1, further comprising one or more of a preservative, wetting agent, emulsifier, dispersant, or anti-oxidant. 5. The liquid dosage form of claim 1, wherein the ratio of bi-cyclic compound to mono-cyclic tautomer is at least about 96:4. 6. The liquid dosage form of claim 1, which is formulated in a capsule. 7. The liquid dosage form of claim 6, which is formulated in a soft capsule. |